Lung cancer is a leading cause of cancer-related deaths, with Non-Small Cell Lung Cancer (NSCLC) comprising 85–90% of cases, most commonly adenocarcinoma. Key mutations include EGFR Exon 19 deletions and Exon 21 L858R. While third-generation TKIs like osimertinib, lazertinib, and aumolertinib are effective, resistance often arises. Amivantamab, a bispecific monoclonal antibody targeting EGFR and c-MET, shows promise, particularly against EGFR Exon 20 insertions.
Objective
To provide a comprehensive evaluation of the adverse effects associated with amivantamab in EGFR-mutant NSCLC, including their underlying pathophysiological mechanisms and evidence-based management strategies. In addition, this review aims to contextualize the clinical relevance of amivantamab by briefly outlining the therapeutic evolution of EGFR-targeted treatments, highlighting the rationale for its development, and current positioning in treatment paradigms.
Methods
A comprehensive review of clinical trials, including CHRYSALIS, PAPILLON, MARIPOSA, and PALOMA-III, was conducted to assess the safety and efficacy of amivantamab. Practical and early insights into managing adverse effects of amivantamab are critical to better adherence and quality of life.
Results
Adverse effects were observed in most of the patients treated with amivantamab. Common side effects included cutaneous toxicities, diarrhea, infusion-related reactions (IRRs), vascular thrombosis and pneumonitis. The most frequent cutaneous side effects were rash, paronychia, pruritis, and stomatitis. Diarrhea occurred in patients primarily due to EGFR inhibition. IRRs were predominantly mild to moderate, occurring mainly during the first cycle. Thrombosis was a notable adverse effect observed, even in patients receiving anticoagulant prophylaxis. Pneumonitis was less common but severe.
Management
Adverse effects of amivantamab are managed based on severity. Cutaneous toxicities are treated with antibiotics, topical steroids, and dose adjustments. Diarrhea is managed with hydration, loperamide, and dose interruption. Infusion-related reactions (IRRs) are treated symptomatically, with epinephrine in severe cases. Anticoagulants are used for deep vein thrombosis or thromboembolism, and fibrinolytics or thrombectomy may be considered. Pneumonitis is managed by discontinuing amivantamab and using glucocorticoids.
Conclusions
Amivantamab is effective for EGFR mutant NSCLC but can cause adverse effects. Understanding these effects and implementing management strategies can optimize outcomes, maintaining treatment efficacy.
SiegelRLGiaquintoANJemalA. Cancer statistics, 2024. CA Cancer J Clin2024; 74: 12–49.
2.
Ünal AAYYSönmezGTenekeciAK. Revolutionizing lung cancer care: the multifaceted approach of artificial intelligence, liquid biopsies, and circulating tumor DNA in screening, diagnosis, and prognosis. Turkish Medical Student Journal2024; 11: 32–39.
3.
TenekeciAUnalACeylanF, et al.An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer. Future Oncol2024; 20: 3019–3038.
4.
KatoTCasariniICoboM, et al.Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: emerging evidence and future perspectives. Lung Cancer2024; 187: 107414.
5.
PiCXuCRZhangMF, et al.EGFR Mutations in early-stage and advanced-stage lung adenocarcinoma: analysis based on large-scale data from China. Thorac Cancer2018; 9: 814–819.
6.
BazhenovaLMinchomAViteriS, et al.Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer2021; 162: 154–161.
7.
RiessJWGandaraDRFramptonGM, et al.Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol2018; 13: 1560–1568.
8.
VyseSHuangPH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther2019; 4: 5.
9.
BillowriaKDas GuptaGChawlaPA. Amivantamab: a new hope in targeting non-small cell lung cancer. Anticancer Agents Med Chem2023; 23: 124–141.
10.
ChoBCSimiASabariJ, et al.Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer2023; 24: 89–97.
11.
MitsudomiTMoritaSYatabeY, et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010; 11: 121–128.
12.
MaemondoMInoueAKobayashiK, et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010; 362: 2380–2388.
13.
RosellRCarcerenyEGervaisR, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol2012; 13: 239–246.
14.
ZhouCWuYLChenG, et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011; 12: 735–742.
15.
NakagawaKGaronEBSetoT, et al.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2019; 20: 1655–1669.
16.
SaitoHFukuharaTFuruyaN, et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol2019; 20: 625–635.
17.
MiyauchiEMoritaSNakamuraA, et al.Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol2022; 40: 3587–3592.
18.
YangJJZhouQYanHH, et al.A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer2017; 116: 568–574.
19.
ParkKTanEHO'ByrneK, et al.Afatinib Versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol2016; 17: 577–589.
20.
WuYLChengYZhouX, et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol2017; 18: 1454–1466.
21.
RamalingamSSVansteenkisteJPlanchardD, et al.Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med2020; 382: 41–50.
22.
LuSDongXJianH, et al.AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol2022; 40: 3162–3171.
23.
ChoBCAhnMJKangJH, et al.Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol2023; 41: 4208–4217.
24.
PlanchardDJänne PasiAChengY, et al.Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med2023; 389: 1935–1948.
25.
ParkKHauraEBLeighlNB, et al.Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol2021; 39: 3391–3402.
26.
ChoBCKimD-WSpiraAI, et al.Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med2023; 29: 2577–2585.
27.
ZhouCTangKJChoBC, et al.Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med2023; 389: 2039–2051.
28.
ChoBCFelipEHayashiH, et al.MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol2022; 18: 639–647.
29.
PassaroAWangJWangY, et al.Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol2024; 35: 77–90.
30.
ZhouCTangKJChoBC, et al.Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions. N Engl J Med2023; 389: 2039–2051.
31.
FelipEChoBCGutiérrezV, et al.Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol2024; 35: 805–816.
32.
LeighlNBAkamatsuHLimSM, et al.Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. J Clin Oncol2024: LBA8505–LBA8505.
33.
ChoBCWangYFelipE, et al.Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): results from CHRYSALIS-2. J Clin Oncol2024; 42: 8516–8516.
34.
WuYLChengYZhouJ, et al.Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med2020; 8: 1132–1143.
35.
ParkKHauraELeighlN, et al.Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol2021; 39: 3391–3402.
36.
GirardNChoBSpiraA, et al.Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone. J Clin Oncol2023; 41: 9137–9137.
37.
ScaltritiMBaselgaJ. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res2006; 12: 5268–5272.
SantosEDSNogueiraKABFernandesLCC, et al.EGFR Targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm2021; 592: 120082.
40.
LondonMGalloE. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int2020; 44: 1267–1282.
41.
YanoSKondoKYamaguchiM, et al.Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res2003; 23: 3639–3650.
42.
Joly-TonettiNOndetTMonshouwerM, et al.EGFR Inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer2021; 21: 5.
43.
LiYFuRJiangT, et al.Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol2022; 12: 804212.
44.
FangHWangYXuL, et al.EGFR Inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins. Int J Mol Med2019; 43: 1522–1530.
45.
TaoGChityalaPK. Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. Toxicol Res (Camb)2021; 10: 476–486.
46.
BowenJM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care2013; 7: 162–167.
47.
Berlanga-AcostaJPlayfordRJMandirN, et al.Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut2001; 48: 803–807.
48.
DuanTCilOThiagarajahJR, et al.Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. JCI Insight2019; 4: e126444.
49.
JayaramAZafeiriouZde BonoJS. Cabozantinib—getting under the skin of cutaneous toxicity. JAMA Oncol2015; 1: 535–536.
50.
CortotALeXSmitE, et al.Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review. Clin Lung Cancer2022; 23: 195–207.
51.
KhoranaAAKudererNMCulakovaE, et al.Development and validation of a predictive model for chemotherapy-associated thrombosis, blood. J Am Soc Hematol2008; 111: 4902–4907.
52.
BolekHÜrünY. Cancer-associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents. Cancer2023; 129: 3216–3229.
53.
MawatariMOkamuraKMatsudaT, et al.Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor. Exp Cell Res1991; 192: 574–580.
54.
GrandeEGiovanniniMMarriereE, et al.Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug–drug interaction study. Br J Clin Pharmacol2021; 87: 2867–2878.
55.
CalifanoRTariqNComptonS, et al.Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs2015; 75: 1335–1348.
56.
AndreyevJRossPDonnellanC, et al.Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol2014; 15: e447–e460.
57.
Freites-MartinezASantanaNArias-SantiagoS, et al.Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed)2021; 112: 90–92.
58.
ChoBFelipEHayashiH, et al.MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. Future Oncol2022; 18: 639–647.
59.
PassaroAWangJWangY, et al.Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol2024; 35: 77–90.
60.
OhmoriTYamaokaTAndoK, et al.Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci2021; 22: 792.
61.
AminMBGreeneFLEdgeSB, et al.The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin2017; 67: 93–99.
62.
BasseCChabanolHBontePE, et al.Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer2022; 173: 116–123.
63.
BarrosoAEstevinhoFHespanholV, et al.Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open2024; 9: 102922.
64.
ContePAsciertoPAPatelliG, et al.Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open2022; 7: 100404.
